- Email: [email protected]
Anti-Egfr Antibody Rechallenge in Chemorefractory Patients with Metastatic Colorectal Cancer
Annals of Oncology 25 (Supplement 5): v75–v109, 2014 doi:10.1093/annonc/mdu436.83
Poster Session (Poster presentations categorized by each organ) P2
10
4
Tatsuhiro Kajitani1, Akitaka Makiyama1,2, Shuji Arita3, Hozumi Kumagai3, Hisanobu Oda1, Tsuyoshi Shirakawa1, Taito Esaki1 1 Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center 2 Department of Hematology/Oncology, Kyushu Kosei Nenkin Hospital 3 Department of Hematology and Medical Oncology, Kyushu University Hospital
abstracts
Background: Anti-EGFR antibody is approved for the treatment of patients with KRAS wild-type metastatic colorectal cancer. However, there are a few studies show the
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v93/2240530 by guest on 26 October 2019
ANTI-EGFR ANTIBODY RECHALLENGE IN CHEMOREFRACTORY PATIENTS WITH METASTATIC COLORECTAL CANCER
efficacy and safety of anti-EGFR antibody rechallenge after disease progression following anti-EGFR antibody based chemotherapy. Patients and methods: We assessed the efficacy and safety of anti-EGFR antibody rechallenge prospectively in patients with metastatic colorectal cancer refractory to anti-EGFR antibody and chemotherapy including oxaliplatin (L-OHP), irinotecan (CPT-11) and FU plus or minus bevacizumab between May 2010 and January 2013. Result: Thirteen patients were enrolled. Nine patients were male and 4 patients were female. The median age of patients was 60 years old, ECOG performance status 0/1; 3/ 10. The median number of previous chemotherapies was 3 (2-5). All patients received prior anti-EGFR antibody therapy, cetuximab (Cmab) + CPT-11; 10 (PR 4), Cmab/ Panitumumab (Pmab) + FOLFOX;2 (PR 2) and Pmab monotherapy; 1 (SD), PFS was 168 days. Anti-EGFR antibody rechallenge therapy were Cmab/Pmab + capecitabine/ S-1 (7), Pmab + FOLFOX (3), Cmab + CPT-11 (2), Pmab monotherapy (1). No CR/PR was obtained, 7 patients had stable disease and 6 patients had progressive disease. Four patients had a minor response. Median overall survival was 228 days and median progression-free survival was 102 days. Adverse events over grade 3 were platelet count decreased (1), paronychia (1), peripheral sensory neuropathy (1), and ileus (1). Conclusion: The efficacy of anti-EGFR antibody rechallenge is limited in chemorefractory patients with metastatic colorectal cancer.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Poster Session (Poster presentations categorized by each organ) P2
10
4
Tatsuhiro Kajitani1, Akitaka Makiyama1,2, Shuji Arita3, Hozumi Kumagai3, Hisanobu Oda1, Tsuyoshi Shirakawa1, Taito Esaki1 1 Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center 2 Department of Hematology/Oncology, Kyushu Kosei Nenkin Hospital 3 Department of Hematology and Medical Oncology, Kyushu University Hospital
abstracts
Background: Anti-EGFR antibody is approved for the treatment of patients with KRAS wild-type metastatic colorectal cancer. However, there are a few studies show the
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v93/2240530 by guest on 26 October 2019
ANTI-EGFR ANTIBODY RECHALLENGE IN CHEMOREFRACTORY PATIENTS WITH METASTATIC COLORECTAL CANCER
efficacy and safety of anti-EGFR antibody rechallenge after disease progression following anti-EGFR antibody based chemotherapy. Patients and methods: We assessed the efficacy and safety of anti-EGFR antibody rechallenge prospectively in patients with metastatic colorectal cancer refractory to anti-EGFR antibody and chemotherapy including oxaliplatin (L-OHP), irinotecan (CPT-11) and FU plus or minus bevacizumab between May 2010 and January 2013. Result: Thirteen patients were enrolled. Nine patients were male and 4 patients were female. The median age of patients was 60 years old, ECOG performance status 0/1; 3/ 10. The median number of previous chemotherapies was 3 (2-5). All patients received prior anti-EGFR antibody therapy, cetuximab (Cmab) + CPT-11; 10 (PR 4), Cmab/ Panitumumab (Pmab) + FOLFOX;2 (PR 2) and Pmab monotherapy; 1 (SD), PFS was 168 days. Anti-EGFR antibody rechallenge therapy were Cmab/Pmab + capecitabine/ S-1 (7), Pmab + FOLFOX (3), Cmab + CPT-11 (2), Pmab monotherapy (1). No CR/PR was obtained, 7 patients had stable disease and 6 patients had progressive disease. Four patients had a minor response. Median overall survival was 228 days and median progression-free survival was 102 days. Adverse events over grade 3 were platelet count decreased (1), paronychia (1), peripheral sensory neuropathy (1), and ileus (1). Conclusion: The efficacy of anti-EGFR antibody rechallenge is limited in chemorefractory patients with metastatic colorectal cancer.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].